Compare Gilead Sciences, Inc. (GILD) vs Omnicom Group Inc. (OMC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs Omnicom Group Inc. — how do they compare? Gilead Sciences, Inc. trades at $136.36 (market cap $163.51B), while Omnicom Group Inc. trades at $81.13 (market cap $23.07B). The key difference: Gilead Sciences, Inc. is far larger — about 7.1× Omnicom Group Inc.'s market cap, and Omnicom Group Inc. pays the higher dividend (3.95%). Which is the better fit depends on your goals.
| GILD | OMC | |
|---|---|---|
Market Cap | $163.51B | $23.07B |
Sector | Health | Media |
52-Week High | $155.80 | $85.80 |
52-Week Low | $108.22 | $67.27 |
Enterprise Value | $178.05B | $30.29B |
Dividend Yield | 2.49% | 3.95% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $133.30, up 2.51% today, with strong technical momentum above key support at $130. The company demonstrates robust fundamentals with a 30.99% net income margin and consistent earnings beats in recent quarters. Recent FDA and EC approvals for Trodelvy in metastatic triple-negative breast cancer highlight growth potential beyond its HIV franchise.
Outlook remains positive with a consensus price target of $152.83 offering 14.6% upside, though risks include patent expirations and competitive pressures. The stock presents a compelling opportunity driven by oncology expansion and strong cash flow generation, supported by overwhelming analyst bullish sentiment.
Omnicom (OMC) trades at $83.28, up 3.13% today, with a bullish technical signal and strong cash flow growth. The stock shows a low P/E of 12.16 and P/S of 0.94, but net income turned negative in 2025. Recent news highlights major client wins like IBM and partnerships with Netflix and Disney, driving positive sentiment. The consensus price target is $105.75, implying 27% upside, with 32% of analysts rating it a Buy.
Outlook: OMC offers value with low valuation multiples and dividend yield, supported by operational strength and AI-driven growth initiatives. Risks include intense competition, margin pressure from the 2025 net loss, and reliance on advertising spending cycles. The stock presents a balanced opportunity for investors seeking exposure to media services with cautious optimism on earnings recovery.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About Omnicom Group Inc.
Omnicom is the world's second- largest ad holding company, based on annual revenue. The firm's services, which include traditional and digital advertising and public relations, are provided worldwide, with over 85% of its revenue coming from more developed regions such as North America and Europe.
Read more on OMC →
